免疫原性对接受皮下英夫利昔单抗治疗的中重度CD患者2年临床结果的影响：对LIBERTY-CD研究3期的事后分析

{"title":"免疫原性对接受皮下英夫利昔单抗治疗的中重度CD患者2年临床结果的影响：对LIBERTY-CD研究3期的事后分析","authors":"","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 7 Suppl 5","pages":"18-19"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397775/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Immunogenicity on 2-Year Clinical Outcomes in Patients With Moderate-to-Severe CD Treated With Subcutaneous Infliximab: A Post Hoc Analysis of the Phase 3 LIBERTY-CD Study.\",\"authors\":\"\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":52498,\"journal\":{\"name\":\"Gastroenterology and Hepatology\",\"volume\":\"21 7 Suppl 5\",\"pages\":\"18-19\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397775/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterology and Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology and Hepatology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}